Redhill Biopharma Ltd (RDHL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.09 is considered Undervalued compared with the five-year average of -7.16. The fair price of Redhill Biopharma Ltd (RDHL) is between 53.19 to 68.75 according to relative valuation method. Compared to the current price of 0.93 USD , Redhill Biopharma Ltd By Undervalued By 98.25%.

Relative Value

Fair Zone

53.19-68.75

Current Price：0.93

98.25%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Redhill Biopharma Ltd (RDHL) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Redhill Biopharma Ltd (RDHL) has a current Price-to-Book (P/B) ratio of -0.42. Compared to its 3-year average P/B ratio of 58.72, the current P/B ratio is approximately -100.72% higher. Relative to its 5-year average P/B ratio of 35.47, the current P/B ratio is about -101.19% higher. Redhill Biopharma Ltd (RDHL) has a Forward Free Cash Flow (FCF) yield of approximately -239.41%. Compared to its 3-year average FCF yield of -308.88%, the current FCF yield is approximately -22.49% lower. Relative to its 5-year average FCF yield of -211.64%, the current FCF yield is about 13.12% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RDHL competitors is 21.93, providing a benchmark for relative valuation. Redhill Biopharma Ltd Corp (RDHL.O) exhibits a P/S ratio of 0.09, which is -99.59% above the industry average. Given its robust revenue growth of -90.21%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RDHL increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RDHL in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RDHL currently overvalued or undervalued?

What is Redhill Biopharma Ltd (RDHL) fair value?

RDHL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Redhill Biopharma Ltd (RDHL) is between 53.19 to 68.75 according to relative valuation method.

How does RDHL's valuation metrics compare to the industry average?

The average P/S ratio for RDHL's competitors is 21.93, providing a benchmark for relative valuation. Redhill Biopharma Ltd Corp (RDHL) exhibits a P/S ratio of 0.09, which is -99.59% above the industry average. Given its robust revenue growth of -90.21%, this premium appears unsustainable.

What is the current P/B ratio for Redhill Biopharma Ltd (RDHL) as of Mar 02 2026?

As of Mar 02 2026, Redhill Biopharma Ltd (RDHL) has a P/B ratio of -0.42. This indicates that the market values RDHL at -0.42 times its book value.

What is the current FCF Yield for Redhill Biopharma Ltd (RDHL) as of Mar 02 2026?

As of Mar 02 2026, Redhill Biopharma Ltd (RDHL) has a FCF Yield of -239.41%. This means that for every dollar of Redhill Biopharma Ltd's market capitalization, the company generates -239.41 cents in free cash flow.

What is the current Forward P/E ratio for Redhill Biopharma Ltd (RDHL) as of Mar 02 2026?

As of Mar 02 2026, Redhill Biopharma Ltd (RDHL) has a Forward P/E ratio of 0.02. This means the market is willing to pay $0.02 for every dollar of Redhill Biopharma Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Redhill Biopharma Ltd (RDHL) as of Mar 02 2026?

As of Mar 02 2026, Redhill Biopharma Ltd (RDHL) has a Forward P/S ratio of 0.09. This means the market is valuing RDHL at $0.09 for every dollar of expected revenue over the next 12 months.

RDHL Valuation